Cross-platform comparisons for targeted bisulfite sequencing of MGISEQ-2000 and NovaSeq6000
Abstract Background An accurate and reproducible next-generation sequencing platform is essential to identify malignancy-related abnormal DNA methylation changes and translate them into clinical applications including cancer detection, prognosis, and surveillance. However, high-quality DNA methylati...
Main Authors: | Jin Sun, Mingyang Su, Jianhua Ma, Minjie Xu, Chengcheng Ma, Wei Li, Rui Liu, Qiye He, Zhixi Su |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-08-01
|
Series: | Clinical Epigenetics |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13148-023-01543-4 |
Similar Items
-
Evaluation of commercial kits for isolation and bisulfite conversion of circulating cell-free tumor DNA from blood
by: Stine H. Kresse, et al.
Published: (2023-09-01) -
Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation
by: Jonathan Dao, et al.
Published: (2023-08-01) -
Combining Solid and Liquid Biopsy for Therapy Monitoring in Esophageal Cancer
by: Florian Richter, et al.
Published: (2023-06-01) -
Sensitive and Specific Analyses of Colorectal Cancer Recurrence through Multiplex superRCA Mutation Detection in Blood Plasma
by: Emma Sandberg, et al.
Published: (2024-01-01) -
BL-MOL-AR Project, Preliminary Results about Liquid Biopsy: Molecular Approach Experience and Research Activity in Oncological Settings
by: Pancrazzi Pancrazzi, et al.
Published: (2023-09-01)